| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | CORT | Common Stock | Options Exercise | $9.15K | +3.03K | +4.12% | $3.02* | 76.6K | Oct 2, 2023 | Direct | F1 |
| transaction | CORT | Common Stock | Sale | -$82.6K | -3.03K | -3.95% | $27.24 | 73.6K | Oct 2, 2023 | Direct | F1, F2, F3 |
| holding | CORT | Common Stock | 10K | Oct 2, 2023 | See Footnote | F4 | |||||
| holding | CORT | Common Stock | 10K | Oct 2, 2023 | See Footnote | F5 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | CORT | Stock option (right to buy) | Options Exercise | $0 | -3.03K | -20.21% | $0.00 | 12K | Oct 2, 2023 | Common Stock | 3.03K | $3.02 | Direct | F6 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | Includes 1,460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 1,658 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, and 456 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. |
| F2 | The transaction was made pursuant to a 10b5-1 plan in effect at the time of this transaction. |
| F3 | Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $27.24 to $27.255. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. |
| F4 | Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. |
| F5 | Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee. |
| F6 | Fully exercisable. |
President, Corcept Endocrinology The power of attorney under which this form was signed is on file with the Commission.